EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.41

11 Feb
2026

-0.560

OPEN

$21.85

-2.55%

HIGH

$22.18

98,506

LOW

$21.15

TARGET
$31.273 46.1% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 133.5 xxx
DPS (cps) xxx 112.9 106.2 xxx
EPS Growth xxx - 22.4% 21.7% xxx
DPS Growth xxx N/A - 5.9% xxx
PE Ratio xxx N/A 15.8 xxx
Dividend Yield xxx N/A 5.0% xxx
Div Pay Ratio(%) xxx 102.9% 79.6% xxx

Dividend yield today if purchased 3 years ago: 2.79%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.35

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 49.19c (franking 95%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic 100.6113.2114.5132.9141.3109.7
DPS All 76.886.094.0107.9114.5112.9
Sales/Revenue 8,765.5 M9,202.9 M10,734.1 M12,237.4 M13,189.1 M12,266.9 M
Book Value Per Share 807.4859.51,195.91,270.51,268.41,348.0
Net Operating Cash Flow 229.2 M298.3 M248.7 M391.4 M348.2 M418.5 M
Net Profit Margin 1.85 %2.01 %1.89 %2.07 %2.06 %1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed 12.71 %13.59 %11.02 %10.78 %11.12 %8.29 %
Return on Invested Capital 9.42 %9.80 %7.40 %7.07 %7.88 %5.70 %
Return on Assets 4.68 %4.82 %3.97 %3.99 %4.12 %3.07 %
Return on Equity 12.71 %13.59 %11.02 %10.78 %11.12 %8.29 %
Return on Total Capital 13.37 %13.68 %11.75 %12.06 %12.64 %10.08 %
Free Cash Flow ex dividends 93.1 M96.2 M12.9 M121.6 M96.2 M156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt 281 M153 M374 M92 M823 M82 M
Long Term Debt 528 M527 M1,273 M1,191 M820 M1,540 M
Total Debt 809 M680 M1,648 M1,283 M1,643 M1,622 M
Goodwill - Gross 970 M999 M2,140 M1,976 M2,068 M2,245 M
Cash & Equivalents - Generic 245 M169 M517 M212 M217 M184 M
Price To Book Value 2.503.502.952.662.322.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex 29.3 M82.3 M89.6 M98.4 M118.8 M146.0 M
Capex % of Sales 0.33 %0.89 %0.84 %0.80 %0.90 %1.19 %
Cost of Goods Sold 8,236 M8,634 M9,985 M11,322 M12,232 M11,346 M
Selling, General & Admin. Exp & Other 269 M281 M404 M470 M474 M497 M
Research & Development ------
Investments - Total 57 M57 M59 M69 M89 M95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

12/12/2025

1

Upgrade to Buy from Accumulate

$34.82

62.63%

Given the share price weakness, Ebos Group is upgraded to Buy from Accumulate, with an unchanged $34.82 price target.

Morgans believes Ebos is a more attractive proposition to the value investor while Sigma Healthcare ((SIG)) will appeal more to a growth investor.

The group is positioned for FY26 as a transition year, moving on from the loss of the Chemist Warehouse contract and large investment in its distribution centre network.

The analyst notes lower capex and an improved return on capital employed of around 15% is anticipated for FY27 and should underwrite longer term shareholder value.

Post the -30% fall in the share price since the August result, Ebos is trading one standard deviation below its 10 year average PE of 22x. The analyst likes the business (and owns the shares) seeing a defensive business returning to good growth with a solid yield.

FORECAST
Morgans forecasts a full year FY26 dividend of 109.00 cents and EPS of 131.50 cents.
Morgans forecasts a full year FY27 dividend of 113.00 cents and EPS of 143.80 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

10/09/2025

2

Overweight

-

-

Jarden notes FY25 marked a reset year for Ebos Group with earnings impacted by the loss of Chemist Warehouse Australia contract, competitive pharmacy pressures, and higher costs from the renewal of distribution centres.

The company expects headwinds to persist through 1H26, with leverage and PBS momentum benefits emerging in FY27.

The broker highlights Animal Care remained a steady performer (around 21% underlying EBITDA), with Next Gen and SVS adding future growth options. SE Asia Medical Devices (Transmedic) delivered strong growth and continues to offer bolt-on M&A opportunities.

Overweight. Target unchanged at $39, as the broker sees FY26 as a transitional year with long-term growth and ROCE momentum resuming from FY27–28.

FORECAST
Jarden forecasts a full year FY26 dividend of 97.00 cents and EPS of 129.60 cents.
Jarden forecasts a full year FY27 dividend of 103.00 cents and EPS of 147.20 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Weekly Ratings, Targets, Forecast Changes – 12-12-25

Dec 15 2025 - Weekly Reports
2
Rudi’s View: Identifying Quality Opportunities

Oct 29 2025 - Rudi's View
3
Weekly Ratings, Targets, Forecast Changes – 19-09-25

Sep 22 2025 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Sep 10, 2025

Sep 10 2025 - Daily Market Reports
5
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps